Page last updated: 2024-10-28
ibudilast and Cardiotoxicity
ibudilast has been researched along with Cardiotoxicity in 1 studies
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Nishiyama, K | 1 |
Numaga-Tomita, T | 1 |
Fujimoto, Y | 1 |
Tanaka, T | 1 |
Toyama, C | 1 |
Nishimura, A | 1 |
Yamashita, T | 1 |
Matsunaga, N | 1 |
Koyanagi, S | 1 |
Azuma, YT | 1 |
Ibuki, Y | 1 |
Uchida, K | 1 |
Ohdo, S | 1 |
Nishida, M | 1 |
Other Studies
1 other study available for ibudilast and Cardiotoxicity
Article | Year |
---|---|
Ibudilast attenuates doxorubicin-induced cytotoxicity by suppressing formation of TRPC3 channel and NADPH oxidase 2 protein complexes.
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cell Line; Cell Survival; Doxorubicin; Humans; Male; | 2019 |